Genetic and clinical phenotypic analysis of carney complex with external auditory canal myxoma

Wei Wan1, Liang Zeng1†, Hongqun Jiang1,2*, Yunyan Xia1,2* and Yuanping Xiong1,2

1Department of Otolaryngology–Head and Neck Surgery, First Affiliated Hospital of Nanchang University, Jiangxi, China, 2Jiangxi Institute of Otorhinolaryngology–Head and Neck Surgery, Jiangxi, China

Background: Mutations in PRKAR1A gene can lead to Carney complex (CNC), and most CNC patients develop cardiac and cutaneous myxomas. In particular, cardiac myxomas are a common cause of mortality in CNC patients. Cutaneous myxomas of the external ear are extremely rare, and do not have any specific clinical features.

Methods: In this retrospective study, we analyzed the clinical and genetic data of the proband and his family and fifty whole blood control samples selected from the molecular genetic database of our hospital. Whole-exome DNA sequencing analysis was used to detect the mutation in the peripheral blood samples.

Results: The results of the clinical analysis showed the presence of spotty skin pigmentation and external auditory canal myxoma in the proband as well as in his sister and mother. Whole-exome DNA sequencing showed a novel heterozygous mutation in the PRKAR1A gene i.e., c.824_825delAG (p.Gln275Leufs*2), in the proband and his sister and mother.

Conclusion: In conclusion, the family members had the same autosomal dominant PRKAR1A mutation. DNA sequencing revealed a novel c.824_825delAG in exon 9 of PRKAR1A. This pathogenic mutation has not been reported previously, and may be related to the occurrence of external auditory canal myxomas and spotty pigmentation. This study broadens the genotypic spectrum of PRKAR1A mutations in CNC.

KEYWORDS carney complex, PRKAR1A gene, mutation-genetics, external auditory canal myxoma, pediatrics

Introduction

Carney complex (CNC) is a rare, autosomal dominant, multiple neoplasia syndrome with various clinical manifestations, including spotty skin pigmentation and myxomas (Carney et al., 1985; Carney, 1995; Briassouli et al., 2012a). Spotty pigmentation may affect any part of the body and develops on the face, lips, and genitalia in approximately...
80% of CNC children (Sandrini and Stratakis, 2003). In addition, most CNC patients develop cardiac and cutaneous myxomas, which are the most common tumors seen in infancy. In particular, cardiac myxomas are a common cause of mortality in CNC patients (Boikos and Stratakis, 2007; Espiar and Bertherat, 2013). Cutaneous myxomas of the external ear are extremely rare, and do not have any specific clinical features, except skin spots before the onset of hearing loss, deafness, and pain due to occlusion of the caused by external auditory canal occlusion. External ear myxomas in CNC, patients can be easily confused with other external auditory canal diseases, and particularly with other tumors (Ferreiro and Carney, 1994). CNC is a common neoplasia syndrome, and associated with endocrine overactivity and multiple tumors (Stratakis et al., 1998; Stratakis et al., 2000), including pituitary adenomas, primary pigmented nodular adrenocortical disease, thyroid tumors, testicular tumors, and ovarian lesions (Stratakis et al., 1997; Stratakis et al., 1999; Pack et al., 2000; Stratakis et al., 2000; Stratakis et al., 2001). A molecular genetic study demonstrated that more than 70% of CNC patients have mutations in the PRKAR1A gene, which is a classic tumor suppressor gene that encodes for the 1-α regulatory subunit (R1α) of the cyclic adenosine monophosphate (cAMP)-dependent protein kinase A (PKA) (Kirschner et al., 2000; Bertherat et al., 2009). PRKAR1A gene mutations cause R1α loss, augment PKA activity, and enhance downstream signaling, which lead to uncontrolled tumor suppression (Kirschner et al., 2000). Moreover, myxomas, acromegaly, and other symptoms are more common in patients with exon mutations than in those with PRKAR1A defects (Bertherat et al., 2009). Horvath (Horvath et al., 2010) reported the functional effects of molecular PRKAR1A mutations, and described the clinical manifestations of specific mutations. Few studies have demonstrated a correlation between specific mutations and CNC manifestations. In this study, we performed genetic and clinical analyses of a Han Chinese family with suspected CNC. The study analyzed the genotype–phenotype correlation in patients CNC patients using clinical phenotyping to laid early CNC diagnosis.

### Materials and methods

The family analyzed in this study were from Jiangxi Province, China. In January 2020, two siblings presented for surgical treatment of unilateral external auditory canal lesions. A detailed medical history was obtained from the parents, the family underwent detailed physical examinations, including ear examinations by a specialist, hearing tests, and adrenal and thyroid ultrasonograms. Tissue samples were obtained from the external auditory canals of the proband and his sister for pathological analysis. Their mother also experienced symptoms of the disease. Whole bloods amples were obtained from the proband and other family members for DNA analysis. Fifty whole blood control samples were randomly selected from the molecular genetic database of our hospital. Informed consent forms was obtained from the participants. Other pathogenic variants of stapes ankylosis were ruled out.

Whole blood samples were collected using 3–5 ml of ethylenediaminetetraacetic acid as an anticoagulant. Genomic DNA from blood samples was used to construct libraries. The target genes and DNA near the shear region were enriched using a Human All Exon V4 kit (BGI Group, Shenzhen, China), and the mutations were detected using the MGISEQ-2000 sequencing platform (BGI Group). The average effective sequencing depth in the target area was ≥100×. The sequences were compared using the Burrows-Wheeler Aligner and UCSC Human Gene Mutation Database (HG19) reference genomes to remove duplicates. GATK was used for genotyping, adjustment of base mass values, and detection of single-nucleotide variants, insertions, deletions. The criteria for pathogenicity were based on the American College of Medical Genetics guidelines. The sequencing results were compared with the HG19, 1,000 Genome, ExAC, ESP6500, GnomAD, dbNSFP, and other databases.

### Results

Three members of the family were diagnosed with CNC, consistent with its autosomal dominant inheritance (Figure 1). The proband’s parents denied inbreeding. The proband and his sister reported progressive hearing loss over the past year, with no history of otitis media, ototoxic drug use, or noise exposure. There were no significant differences in growth and development compared to other patients and peers. Spotty pigmentation was found in the fingers, face, and lingual dorsal mucosa of the proband and his sister and mother (Figure 2). The proband and his sister had well-demarcated unilateral external auditory canal lesions. Ear computed tomography revealed slight low-density filling of the affected external auditory canal and its bony walls. Pure-tone audiometry showed ipsilateral conductive deafness. Histopathology suggested a diagnosis of external auditory canal myxoma (Figure 4). PRKAR1A DNA sequencing indicated a novel site mutation, c.824_825delAG (p.Gln275Leufs*2), in exon 9. Ultrasonography of the proband revealed a low-density mass in the left atrium and right ventricle, with no significant enhancement (Figure 3). No cardiac myxomas were found in the remaining family members on echocardiography. Adrenal and thyroid gland ultrasonography showed no obvious abnormalities. Histopathologically, the tumor samples of the proband and his sister were composed of spindle or stellate cells associated with mucous stroma and small blood vessels. Immunohistochemistry showed tumor cells, consistent with the myxoma (Figure 4).
Whole-exome DNA sequencing showed a novel heterozygous mutation in the PRKAR1A gene i.e., c.824_825delAG (p.Gln275Leufs*2), in the proband and his sister and mother (Figure 5). To confirm that this was a pathogenic mutation, we screened 50 healthy controls for the PRKAR1A gene. None of the controls had the mutation; therefore, suggesting that it was pathogenic rather than polymorphic.
We searched the PubMed database to identify literature on the PRKAR1A gene. More than 140 PRKAR1A pathogenic mutations were identified in the PRKAR1A Mutation (http://PRKAR1A.nichd.nih.gov) and PRKAR1A databases, most of which were located in exons. We identified a heterozygous mutation (c.824_825delAG) not found in any large next-generation sequencing (ExAC and GnomAD) or public single nucleotide polymorphism databases (Figure 6). PROVEN was used to predict the profiles of proteins potentially generated by this mutation. We found that the mutation introduced a premature stop codon, which led to truncated translation of 277 amino acids and a truncated protein. Moreover, this mutation significantly affected secondary structure predictions of the RIa domain.

Discussion

CNC is an autosomal dominant syndrome; a positive family history is present in approximately 70% of patients (Bertherat...
et al., 2009). The wild-type PRKAR1A-encoding DNA sequence contains 1,146 bases, and produces a protein containing 381 amino acids (Fu et al., 2018). Approximately 62% of CNC patients have inactivated mutations which are encoded by the PRKAR1A gene in the R1α domain of cAMP-dependent PKA (Kirschner et al., 2000; Robinson-White et al., 2003; Tsilou et al., 2004; Bertherat et al., 2009). Biochemically, inactivation of the R1α regulatory subunit enhances PKA activity and downstream signaling (Bertherat et al., 2009). CNC is heterogeneous condition involving 2p16 (CNC2) and 17q22_24 (CNC1) (Matyakhina et al., 2003). Approximately 80% of the pathogenic PRKAR1A variants are affected by mRNA nonsense-mediated decay of the mutant sequence, which affects PRKAR1A haploinsufficiency by causing deletions in the mutant protein (Bertherat et al., 2009; Bonnet-Serrano and Bertherat, 2018; Kamilaris et al., 2019). In the present study, we report a novel mutation in the mRNA coding region within exon 9 of the PRKAR1A gene. Based on the DNA sequencing results, we hypothesized that the deletion altered the coding protein at 275aa (Gln to Leu), which changed the amino acid at 277 to a terminating amino acid, and resulted in a truncated protein. The cAMP nucleotide binding domain B in PKA was inactivated;
therefore, cAMP failed to bind with the PKA regulatory subunit and release the catalytic subunit. Consequently, regulation of the PKA catalytic subunit was lost, leading to activation of the cAMP-PKA pathway, increased mitosis and cell proliferation (Amieux and McKnight, 2002; Kamilaris et al., 2019) (Figure 7).

Previous studies have demonstrated that PRKAR1A haploinsufficiency and overactivity may lead to eyelid myxomas (Robinson-White et al., 2003; Tsilou et al., 2004; Rothenbuhler and Stratakis, 2010; Kamilaris et al., 2019), consistent with our findings of external auditory canal myxomas.

CNC is a rare syndrome with two main manifestations verified histologically, biochemically, or by imaging. Patients with a single manifestation have an inactivating PRKAR1A mutation or first-degree relative with CNC (Carney et al., 1985; Kamilaris et al., 2019). Although skin pigmentation is useful for early diagnosis of CNC, it is not always observed in the early stages, and other signs are required for an accurate diagnosis (Carney et al., 1986; Ferreiro and Carney, 1994).

The most common tumors of infancy in CNC patients are cardiac and cutaneous myxomas of the eyelid, breast, ear, and external genitalia (Ferreiro and Carney, 1994). Isolated ear myxomas unrelated to CNC are rare (Palva et al., 1991), and thus diagnostically important. Most external auditory myxomas are misdiagnosed as polyps or tumors, which are amenable to simple excision. External ear myxomas have no specific histopathological features and should be differentiated from fibroepithelial polyps and papillomas, squamous papillomas, ear polyps, and hamartomas (Ferreiro and Carney, 1994).

External auditory canal myxomas are pathologically similar to cutaneous myxomas. These mucoid lesions are covered with keratinized squamous epithelium and exhibit obvious basaloid bud proliferation. The lesion consists of scattered stellate and spindle cells, with lymphocyte infiltration (Ferreiro and Carney, 1994; Rothenbuhler and Stratakis, 2010). Previous descriptions are consistent with our pathological finding.

CNC is a rare autosomal dominant disease, but the relationships among its clinical manifestations, phenotypes, and genetic profile are not clear. Most previous reports external auditory canal myxomas in CNC patients were isolated cases. Briassoulis (Briassoulis et al., 2012b) reported a myxoma behind the right ear in the 23-month-old daughter of a CNC patient. A PRKAR1A was detected in this patient, her sister, and mother, but only the patient had an external auditory myxomas. In the present study, external auditory myxomas were detected in early childhood in all CNC patients in this family. Therefore, we speculated that the c.824_825delAG mutation might be related to the clinical manifestations observed in this family, but this requires further validation.

In conclusion, the proband and his sister and mother had spotty pigmentation and external ear myxomas. The family members had the same autosomal dominant PRKAR1A mutation. DNA sequencing revealed a novel c.824_825delAG mutation in exon 9 of PRKAR1A. This pathogenic mutation (PVS1+PM2) has not been reported previously, and may be related to the occurrence of
external auditory canal myxomas and spotty pigmentation. This study broadens the genotypic spectrum of PRKAR1A mutations in CNC, and may lead to a better understanding of CNC pathogenesis.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Nanchang University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

YXia and HJ designed the study and revised the manuscript. WW and LZ collected the data and wrote the manuscript. YXio prepared the figures. All authors contributed to the article and approved the submitted version.

References

Amieux, P. S., and McKnight, G. S. (2002). The essential role of RI alpha in the maintenance of regulated PKA activity. Ann. N. Y. Acad. Sci. 968, 75–95. doi:10.1111/j.1749-6632.2002.tb04328.x

Bertherat, J., Horvath, A., Groussin, L., Grubar, S., Boikos, S., Cazabat, L., et al. (2009). Mutations in regulatory subunit type Iα of cyclic adenosine 3′-5′-monophosphate-dependent protein kinase (PRKARIA): Phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab. 94 (6), 2085–2091. doi:10.1210/jc.2008-2333

Boikos, S. A., and Stratakis, C. A. (2007). Carney complex: The first 20 years. Curr. Opin. Oncol. 19 (1), 24–29. doi:10.1097/COO.0b013e32801195eb

Bonnet-Serrano, F., and Bertherat, J. (2018). Genetics of tumors of the adrenal cortex. Endocr. Relat. Cancer 25 (3), R131–r152. doi:10.1530/erc-17-0361

Brassoulou, G., Kuburovic, V., Xekouki, P., Patronas, N., Keil, M. F., Lysikatos, C., et al. (2012). Recurrent left atrial myxomas in Carney complex: A genetic cause of multiple strokes that can be prevented. J. Stroke Cerebrovasc. Dis. 21 (8), 914.e1–8. doi:10.1016/j.jstrokecerebrovasdis.2012.01.006

Brassoulou, G., Quezado, M., Lee, C. C., Xekouki, P., Keil, M., and Stratakis, C. A. (2012). Myxoma of the ear lobe in a 23-month-old girl with Carney complex. J. Cutan. Pathol. 39 (1), 68–71. doi:10.1111/j.1600-0560.2011.01786.x

Carney, J. A., Gordon, H., Carpenter, P. C., Shenoy, B. V., and Go, V. L. (1985). The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine 64 (4), 270–283. doi:10.1097/00005792-198507000-00007

Carney, J. A., Headington, J. T., and Su, W. P. (1986). Cutaneous myxomas. A major component of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Arch. Dermatol. 122 (7), 790–798. doi:10.1001/archderm.122.7.790

Carney, J. A. (1995). The Carney complex (myxomas, spotty pigmentation, endocrine overactivity, and schwannomas). Dermatol. Clin. 13 (1), 19–26. doi:10.1016/s0733-8635(18)30102-5

Espiard, S., and Bertherat, J. (2013). Carney complex. Front. Horm. Res. 41, 50–62. doi:10.1159/000345669

Ferreiro, J. A., and Carney, J. A. (1994). Myxomas of the external ear and their significance. Am. J. Surg. Pathol. 18 (3), 274–280. doi:10.1097/00000478-199403000-00007

Fu, J., Lai, F., Chen, Y., Wan, X., Wei, G., Li, Y., et al. (2018). A novel splice site mutation of the PRKARIA gene, C440+5G>C, in a Chinese family with Carney complex. J. Endocrinol. Invest. 41 (8), 909–917. doi:10.1007/s40618-017-0817-5

Horvath, A., Bertherat, J., Groussin, L., Guillaud-Bataille, M., Tsang, K., Cazabat, L., et al. (2010). Mutations and polymorphisms in the gene encoding regulatory subunit type 1α of the protein kinase A (PRKARIA): An update. Hum. Mutat. 31 (4), 369–379. doi:10.1002/humu.21178

Kamilaris, C. D. C., Fauze, F. R., Voutetakis, A., and Stratakis, C. A. (2019). Carney complex. Exp. Clin. Endocrinol. diabetes official J. 127 (2–3), 156–164. German Society of Endocrinology [and] German Diabetes Association. doi:10.1055/a-0753-4943

Funding

This work was supported by the Jiangxi Provincial Natural Science Foundation Project (Grant No. 20192BAB205051) and Health and Family Planning Commission of Jiangxi Province Plan Project (202110012). National Natural Science Foundation of China (82171116), and Central Funds Guiding the Local Science and Technology Development (20221ZDG020066).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.947305/full#supplementary-material
Kirschner, L. S., Carney, J. A., Pack, S. D., Taymans, S. E., Giatzakis, C., Cho, Y. S., et al. (2000). Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. *Nat. Genet.* 26 (1), 89–92. doi:10.1038/79238

Matyakhina, L., Pack, S., Kirschner, L. S., Pak, E., Mannan, P., Jaikumar, J., et al. (2003). Chromosome 2 (2p16) abnormalities in Carney complex tumours. *J. Med. Genet.* 40 (4), 268–277. doi:10.1136/jmg.40.4.268

Pack, S. D., Kirschner, L. S., Pak, E., Zhuang, Z., Carney, J. A., and Stratakis, C. A. (2000). Genetic and histologic studies of somatomammotrophic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). *J. Clin. Endocrinol. Metab.* 85 (10), 3860–3865. doi:10.1210/jcem.85.10.6875

Palva, T., Saksela, E., and Ramsay, H. (1991). Myxoma of the external auditory meatus. *J. Laryngol. Otol.* 105 (5), 364–366. doi:10.1017/s0022215100116019

Robinson-White, A., Hundley, T. B., Shiferaw, M., Bertherat, J., Sandrini, F., and Stratakis, C. A. (2003). Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. *Hum. Mol. Genet.* 12 (13), 1473–1484. doi:10.1093/hmg/ddg160

Rothenbuhler, A., and Stratakis, C. A. (2010). Clinical and molecular genetics of Carney complex. *Best. Pract. Res. Clin. Endocrinol. Metab.* 24 (3), 389–399. doi:10.1016/j.beem.2010.03.003

Sandrini, F., and Stratakis, C. (2003). Clinical and molecular genetics of Carney complex. *Mol. Genet. Metab.* 78 (2), 83–92. doi:10.1016/s1096-7192(03)00606-4

Stratakis, C. A., Courcoutakis, N. A., Abati, A., Filie, A., Doppman, J. L., Carney, J. A., et al. (1997). Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). *J. Clin. Endocrinol. Metab.* 82 (7), 2037–2043. doi:10.1210/jcem.82.7.4274079

Stratakis, C. A., Kirschner, L. S., and Carney, J. A. (1998). Carney complex: Diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. *Am. J. Med. Genet.* 80 (2), 183–185. doi:10.1002/(sici)1098-6626(19981110)80:2<183::aid-ajmg19>3.0.co;2-i

Stratakis, C. A., Kirschner, L. S., and Carney, J. A. (2001). Clinical and molecular features of the Carney complex: Diagnostic criteria and recommendations for patient evaluation. *J. Clin. Endocrinol. Metab.* 86 (9), 4041–4046. doi:10.1210/jcem.86.9.7903

Stratakis, C. A., Papageorgiou, T., Premkumar, A., Pack, S., Kirschner, L. S., Taymans, S. E., et al. (2000). Ovarian lesions in Carney complex: Clinical genetics and possible predisposition to malignancy. *J. Clin. Endocrinol. Metab.* 85 (11), 4359–4366. doi:10.1210/jcem.85.11.6921

Stratakis, C. A., Sarlu, N., Kirschner, L. S., Carney, J. A., Doppman, J. L., Nieman, L. K., et al. (1999). Paradoxical response to dexamethasone in the diagnosis of primary pigmented nodular adrenocortical disease. *Ann. Intern. Med.* 131 (8), 585–591. doi:10.7326/0003-4819-131-8-199910190-00006

Tsaiou, E. T., Chan, C. C., Sandrini, F., Rubin, B. I., Shen, D. F., Carney, J. A., et al. (2004). Eyelid myxoma in Carney complex without PRKAR1A allelic loss. *Am. J. Med. Genet.* A 130a (4), 395–397. doi:10.1002/ajmg.a.30279